LDL Cholesterol: Why the Number Alone Isn't Enough

If you're making clinical decisions based on LDL-C alone, you're working with roughly 70% of the picture — and for about one in four clients, the number is actively misleading.

The standard lipid panel gives you total cholesterol, LDL-C, HDL-C, and triglycerides. For decades, cardiovascular risk assessment has centered on LDL-C — the assumption being that higher LDL cholesterol means higher risk. That assumption is incomplete, and in a significant percentage of cases, it's wrong.

This article breaks down why LDL-C alone is an unreliable risk marker, what to look at instead, and how the Three-Tier Decision Tree changes the way you approach a lipid panel.

The Fundamental Problem: Cargo vs. Vehicles

LDL-C measures the cholesterol content carried inside LDL particles — the cargo. It does not measure the number of particles doing the carrying. This distinction is the single most important concept in modern lipid assessment.

The analogy that makes it click: traffic congestion is caused by the number of vehicles on the road, not the number of passengers inside them. A cruise ship can carry thousands of passengers in a single berth. Put those same people on individual boats and the marina is overwhelmed. When it comes to atherogenesis, the particle count — not the cholesterol concentration — drives the process.

Data from the Framingham Offspring Study demonstrated that LDL particle number (LDL-P) was a significantly stronger predictor of future cardiovascular events than LDL-C, particularly in cases where the two measures were discordant.¹ The EPIC-Norfolk study confirmed this in a large apparently healthy population, finding that LDL-P predicted coronary artery disease on top of traditional risk factors, even after adjusting for LDL-C.²

ApoB: The Better Marker

Each atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a) — carries exactly one apolipoprotein B molecule on its surface. That makes ApoB a direct, countable measure of total atherogenic particle burden. Unlike LDL-C, it doesn't depend on assumptions about particle composition.

A 2024 review in Circulation concluded that ApoB measurement outperforms LDL-C in predicting atherosclerotic cardiovascular disease and should be incorporated into risk assessment and treatment monitoring.³ A systematic review in Pharmacological Research confirmed that ApoB (as a proxy for LDL particle number) was associated with incident cardiovascular disease and outperformed LDL-C in the majority of studies examined.⁴

Michael's functional optimal range for ApoB is <90 mg/dL, compared to the conventional threshold of <100 mg/dL. When ApoB is available on a panel, it provides a more reliable single measure of atherogenic risk than LDL-C.

Small Dense LDL: Why Size Matters

LDL particles exist on a spectrum from large and buoyant to small and dense. The clinical significance of this spectrum is substantial. Small, dense LDL particles increase cardiovascular risk approximately threefold because they penetrate arterial walls more easily, are more susceptible to oxidation, and have a longer half-life in circulation.

The critical connection for functional practitioners: insulin resistance is one of the primary drivers of the shift toward small dense LDL. Research using nuclear magnetic resonance spectroscopy has demonstrated that insulin resistance and type 2 diabetes are independently associated with increased small LDL particle concentration and decreased LDL particle size — even after controlling for triglyceride levels.⁵ Additionally, LDL particle size has been shown to identify at-risk individuals who would be missed by LDL-C, non-HDL-C, or triglycerides alone.⁶

TG/HDL Ratio: The Most Underused Marker on a Standard Panel

If a standard lipid panel is all you have to work with — no LDL-P, no ApoB, no particle size testing — the TG/HDL ratio is your single most informative number for metabolic and cardiovascular risk.

The TG/HDL-C ratio is closely correlated with insulin resistance, central obesity, and metabolic syndrome, and has been validated as a strong independent risk marker for cardiovascular disease across multiple populations.⁷ It has been shown to be more closely linked to insulin resistance than either triglycerides or HDL alone, with optimal cutoffs ranging from 2.0 to 3.5 depending on ethnicity and sex.⁸

Michael's functional optimal: TG/HDL ratio <2.0. A ratio above 3.5 strongly correlates with the small dense LDL pattern — meaning you can infer particle quality from a standard panel without ordering advanced testing.

The Context Problem: What's Driving the Cholesterol?

Cholesterol is a check engine light for the body. When there's dysfunction or chronic illness, it frequently shows up in the lipid profile. Covering it up without investigating the cause is like putting tape over the dashboard light.

Multiple upstream drivers affect cholesterol and need to be assessed before drawing conclusions:

Insulin resistance shifts the particle profile toward small dense LDL, raises triglycerides, and lowers HDL — the classic atherogenic triad. This is the most common driver and the reason the Three-Tier Decision Tree places blood sugar assessment first.

Thyroid dysfunction directly impacts cholesterol clearance. The liver has T3 receptors — without adequate thyroid hormone, these receptors aren't activated, and the liver doesn't clear cholesterol efficiently from the blood. This is why hypothyroidism frequently presents with elevated total cholesterol and LDL-C that resolves when thyroid function is optimized.

Inflammation triggers LDL oxidation, which is the actual mechanism of arterial damage. Elevated hs-CRP alongside a concerning lipid panel is a different clinical picture than dyslipidemia without inflammation.

Iron overload has been shown to accelerate carotid atherosclerosis, likely through iron-catalyzed oxidative stress on lipids. One clinical observation: patients with dyslipidemia despite good metabolic health — check ferritin. If it's elevated, address the iron. Lipids often improve over months without any direct lipid intervention.

LDL Isn't Just a Risk Marker

An often-overlooked fact: LDL plays an active role in immune defense. Research has demonstrated that LDL particles directly bind to and neutralize bacterial endotoxins, preventing inflammatory cascades that would otherwise be triggered by gram-negative bacteria.⁹

This is one reason why the relationship between cholesterol and mortality isn't linear. A systematic review of elderly populations found that LDL-C was not associated with cardiovascular disease mortality, and was inversely associated with all-cause mortality in most people over 60.¹⁰ Additionally, cholesterol levels below 160 mg/dL have been associated with increased mortality from non-cardiovascular causes.

The takeaway isn't that high cholesterol is harmless. It's that cholesterol serves essential physiological functions — immune defense, hormone synthesis, cell membrane integrity, brain function (the brain contains 20% of the body's total cholesterol) — and that assessment must account for context, particle characteristics, and upstream drivers rather than targeting a single number.

Functional Optimal Ranges: Lipid Panel